Stockwatch: UniQure's guile and the dubious promise of gene therapy
This article was originally published in Scrip
After last week's headline-grabbing deal between Bristol Myers Squibb (BMS) and Dutch gene therapy company uniQure (scripintelligence.com, 6 April 2015), who would have thought that events in Europe might by the end of the week spell the demise of uniQure's gene therapy platform?
You may also be interested in...
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.